When multiple myeloma relapses

RESPOND with a Kyprolis®-based regimen

KRd progression-free survival after one relapse

In a post-hoc analysis of the ASPIRE trial, KRd achieved a PFS of nearly 30 months among patients with only one relapse (29.6 months with KRd vs 17.6 months with Rd; descriptive P=0.008).1

Adapted from Dimopoulos et al.1

Kyprolis® has a tolerable safety profile in combination with Rd Detailed treatment regimen in the KRd pivotal phase 3 ASPIRE study

Starting a Kyprolis®-based regimen as the 1st treatment after relapse added one additional year of median PFS vs Rd1

*Descriptive P value.

Please read the SmPC for full comprehensive safety information

References

  1. Dimopoulos MA et al. Presented at the 20th Congress of EHA; 11–14 June 2015; Vienna, Austria. Abstract S427.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis